FIELD OF INVENTION
[001] The present disclosure relates to a composition for inhibiting growth of microorganisms on skin, said composition comprising synergistic concentrations of EDTA and at least one essential oil. Also provided are formulations comprising said compositions, and methods of preparing the same.
BACKGROUND OF THE INVENTION
[002] Microorganisms that generally reside in follicles, pores and surface of human skin are referred to as microflora. A majority of such microorganisms are gram-positive and are beneficial in occupying a niche and denying access to transients, which may be harmful, infectious and pathogenic. Some examples of such microflora are Staphylococcus epidermidis, Staphylococcus aureus (S. aureus), and Gram-Negative Bacilli (Escherichia coli). Different microflora have different properties and cause different diseases. For instance, Staphylococcus aureus is a common resident of skin and mucous membranes of humans. The Staphylococcus aureus is a common cause of skin infections such as boils, heat rash, also referred to as prickly heat. Further, Staphylococcus aureus cause some life threatening bacterial infections. Other diseases caused by such microflora include Toxic shock syndrome, Scalded skin syndrome, food poisoning.
[003] Antimicrobial products such as, emulsions, lotions, creams, ointments, salves, powders, suspensions, gels, soaps, are available to control multiplication of the microflora and pathogenic microorganisms present on the skin. Prior art describes antimicrobial products that contain antimicrobial agents used to kill pathogenic microorganisms. However high concentrations of such antimicrobial agent is required to kill a specific pathogenic microorganism, and this has an undesirable side effect of killing friendly and useful microorganisms.

SUMMARY OF THE INVENTION
[004] In an aspect of the present disclosure, there is provided a composition comprising synergistic concentrations of (a) Ethylenediamine Tetraacetic Acid (EDTA), and (b) at least one essential oil selected from the group consisting of Ajwain seed oil (Trachyspermum copticum) and Lavender tea tree oil (Melaleuca ericifolia). [005] In an aspect of the present disclosure, there is provided a formulation comprising of a composition, said composition comprising synergistic concentrations of (a) Ethylenediamine Tetraacetic Acid (EDTA), and (b) at least one essential oil selected from the group consisting of Trachyspermum copticum oil and Melaleuca ericifolia oil.
[006] In an aspect of the present disclosure, there is provided a personal cleansing formulation comprising (a) at least one fatty acid in a range of 10 to 25% by weight; (b) at least one alkali in a range of 0.001 to 5% by weight; (c) at least one solubilizer in a range of 5 to 40% by weight; (d) optionally at least one chelating agent in a range of 0.001 to 5 % by weight; (e) EDTA in a range of 62.5 – 125 ppm; and Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or Melaleuca ericifolia oil in a range of 3125 – 6250 ppm; and (f) water in a range of 30 to 70 % by weight.
[007] In an aspect of the present disclosure, there is provided a personal cleansing formulation comprising (a) at least one surfactant in a range of 2 to 20% by weight; (b) at least one polymer in a range of 0.1 to 15% by weight; (c) at least one solubilizer in a range of 0 to 10% by weight; (d) EDTA in a range of 62.5 – 125 ppm; and Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or Melaleuca ericifolia oil in a range of 3125 – 6250 ppm; and (e) water to make up 100 % by weight.
[008] In an aspect of the present disclosure, there is provided a soap bar formulation comprising (a) at least one sodium salts of fatty acids in a range of 30-95% by weight; (b) at least one humectant and emollient in a range of 0.5 to 10 % by weight; (c) at least one binder in a range of 0.5 to 10% by weight; (d) optionally at least one

opacifier in a range of 0.001 to 3% by weight; (e) EDTA in a range of 62.5 – 125 ppm; and Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or Melaleuca ericifolia oil in a range of 3125 – 6250 ppm.
[009] In an aspect of the present disclosure, there is provided a topical anti-microbial formulation comprising:
i. at least one chelating agent in a range of 0.001-5% by weight;
ii. at least one polymer in a range of 0.005-5% by weight;
iii. at least one emulsifying agent in a range of 0.01-5% by weight;
iv. at least one humectant in a range of 0.01-10% by weight;
v. at least one preservative in a range of 0.001-1% by weight;
vi. optionally, at least one neutralizing agent in a range of 0-0.75% by
weight;
vii. EDTA in a range of 62.5 – 125 ppm;
viii. Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or
Melaleuca ericifolia oil in a range of 3125 – 6250 ppm; and
ix. water in a range of 71-99.9% by weight.
[0010] These and other features, aspects, and advantages of the present subject matter will be better understood with reference to the following description and appended claims. This summary is provided to introduce a selection of concepts in a simplified form. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS
[0011] The detailed description is described with reference to the accompanying figures. In the figures, the left-most digit(s) of a reference number identifies the figure in which the reference number first appears. The same numbers are used throughout the drawings to reference like features and components.

[0012] Figure 1 is a schematic of the checkerboard microbial assay to identify synergistic combination of actives that inhibit growth of microorganisms on human skin, in accordance with an embodiment of the present disclosure.
DETAILED DESCRIPTION OF THE INVENTION
[0013] Those skilled in the art will be aware that the present disclosure is subject to
variations and modifications other than those specifically described. It is to be
understood that the present disclosure includes all such variations and modifications.
The disclosure also includes all such steps, features, compositions and compounds
referred to or indicated in this specification, individually or collectively, and any and
all combinations of any or more of such steps or features.
Definitions
[0014] For convenience, before further description of the present disclosure, certain
terms employed in the specification, and examples are collected here. These
definitions should be read in the light of the remainder of the disclosure and
understood as by a person of skill in the art. The terms used herein have the meanings
recognized and known to those of skill in the art, however, for convenience and
completeness, particular terms and their meanings are set forth below.
[0015] The articles “a”, “an” and “the” are used to refer to one or to more than one
(i.e., to at least one) of the grammatical object of the article.
[0016] The terms “comprise” and “comprising” are used in the inclusive, open sense,
meaning that additional elements may be included. It is not intended to be construed as
“consists of only”.
[0017] Throughout this specification, unless the context requires otherwise the word
“comprise”, and variations such as “comprises” and “comprising”, will be understood
to imply the inclusion of a stated element or step or group of element or steps but not
the exclusion of any other element or step or group of element or steps.
[0018] The term “including” is used to mean “including but not limited to”.
“Including” and “including but not limited to” are used interchangeably.
5

[0019] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, the preferred methods, and materials are now described. All publications mentioned herein are incorporated herein by reference.
[0020] A composition comprising “synergistic activity” or a “synergistic composition” is a combination of compounds which exhibits increased biological or functional activity as a non-linear multiple of the biological or functional activity of the individual compounds. In other words, the combined biological or functional activity of two or more compounds being tested is significantly greater than the expected result based on independent effects of the compounds when tested separately. Synergy may be apparent only at some ranges or concentrations.
[0021] The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for the purposes of exemplification only. Functionally-equivalent products, compositions, and methods are clearly within the scope of the disclosure, as described herein.
[0022] In an embodiment of the present disclosure, there is provided a composition comprising synergistic concentrations of (a) EDTA and (b) at least one essential oil selected from the group consisting of Trachyspermum copticum oil and Melaleuca ericifolia oil.
[0023] In an embodiment of the present disclosure, there is provided a composition comprising synergistic concentrations of (a) EDTA in a range of 62.5 – 125 ppm and (b) at least one essential oil selected from the group consisting of Trachyspermum copticum oil and Melaleuca ericifolia oil.
[0024] In an embodiment of the present disclosure, there is provided a composition comprising synergistic concentrations of EDTA in a range of 62.5 – 125 ppm and Trachyspermum copticum oil in the range of 390.625 - 781.25 ppm.

[0025] In an embodiment of the present disclosure, there is provided a composition comprising synergistic concentrations of EDTA in a range of 62.5 - 125 ppm and Melaleuca ericifolia oil in the range of 3125 - 6250 ppm.
[0026] In an embodiment of the present disclosure, there is provided a composition comprising of (a) EDTA; and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein the said composition comprises synergistic concentrations of (a) EDTA in a range of 62.5 - 125 ppm, and (b) Trachyspermum copticum oil in the range of 390.625 - 781.25 ppm, or Melaleuca ericifolia oil in the range of 3125 - 6250 ppm. [0027] In an embodiment of the present disclosure, there is provided a composition comprising of a) EDTA, and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein synergistic concentrations of EDTA in said composition is 62.5 ppm, Trachyspermum copticum oil in said composition is 390.6 ppm or Melaleuca ericifolia oil in said composition is 3125 ppm.
[0028] In an embodiment of the present disclosure, there is provided a composition comprising synergistic concentrations of (a) EDTA, and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein the said composition inhibits growth of at least one microorganism which include but is not limited to Staphylococcus aureus (S aureus) and Escherichia coli (E coli).
[0029] In an embodiment of the present disclosure, there is provided a composition comprising of (a) EDTA, and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein synergistic concentration of (a) EDTA in the said composition is 62.5 ppm, and (b) Trachyspermum copticum oil in the said composition is 390.6 ppm, or Melaleuca ericifolia oil in the said composition is 3125 ppm, wherein the said composition inhibits growth of at least one microorganism which include but is not limited to Staphylococcus aureus (S aureus) and Escherichia coli (E coli). [0030] In an embodiment of the present disclosure, there is provided a composition comprising of (a) EDTA, and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein synergistic concentrations of (a) EDTA in the said composition is in the range of 62.5 - 125 ppm, and (b) Trachyspermum copticum oil in the said composition

is in the range of 390.625 - 781.25 ppm, or Melaleuca ericifolia oil in the said
composition is in the range of 3125 – 6250 ppm, wherein the said composition inhibits
growth of at least one microorganism which include but is not limited to
Staphylococcus aureus (S. aureus) and Escherichia coli (E coli).
[0031] In an embodiment of the present disclosure, there is provided a composition
comprising of a synergistic ratio of EDTA and Trachyspermum copticum oil in the
range of 1:3 to 1:13.
[0032] In an embodiment of the present disclosure, there is provided a composition
comprising a synergistic ratio of EDTA and Melaleuca ericifolia oil in the range of
1:20 to 1:100.
[0033] In an embodiment of the present disclosure, there is provided a composition
comprising a synergistic ratio of EDTA and Trachyspermum copticum oil in the range
of 1:3 to 1:13, wherein the said composition inhibits growth of at least one
microorganism which include but is not limited to Staphylococcus aureus (S. aureus)
and Escherichia coli (E coli).
[0034] In an embodiment of the present disclosure, there is provided a composition
comprising a synergistic ratio of EDTA and Melaleuca ericifolia oil in the range of
1:20 to 1:100, wherein the said composition inhibits growth of at least one
microorganism which include but is not limited to Staphylococcus aureus (S. aureus)
and Escherichia coli (E coli).
[0035] In an embodiment of the present disclosure, there is provided a formulation
comprising of a) EDTA, and b) Trachyspermum copticum oil or Melaleuca ericifolia
oil, wherein synergistic concentrations of (a) EDTA is in the range of 62.5 – 125 ppm,
and (b) Trachyspermum copticum oil is in the range of 390.625 - 781.25 ppm, or
Melaleuca ericifolia oil is in the range of 3125 – 6250 ppm.
[0036] In an embodiment of the present disclosure, there is provided a formulation
comprising of a) EDTA, and b) Trachyspermum copticum oil or Melaleuca ericifolia
oil, wherein synergistic ratios of (a) EDTA and Trachyspermum copticum oil is in the

range of 1:3 to 1:13; or (b) synergistic ratio of EDTA and Melaleuca ericifolia oil is in
the range of 1:20 to 1:100.
[0037] In an embodiment of the present disclosure, there is provided a formulation as
described herein, wherein said formulation further comprising of one or more
cosmetically acceptable excipients selected from the group consisting of fatty acids,
alkalis, viscosity modifiers, polymers, humectants, colors, fragrances, surfactants,
chelating agents, emulsifying agents, emollients and diluents.
[0038] In an embodiment of the present disclosure, there is provided a formulation
comprising one or more cosmetically acceptable excipients, the excipients used for
preparation of formulation are indicated in Table 1.

[0039] In an embodiment of the present disclosure, there is provided a formulation as
described herein, wherein the said formulation further comprising at least one: i)
polymer selected from the group consisting of (a) at least one starch; (b) at least one
modified starch; (c) at least one gum; (d) at least one carbomer; (e) at least one silicone
based polymer; (f) at least one acrylate; (g) at least one cellulose based polymer; and
(h) combinations thereof; ii) Chelating agent selected from the group consisting of
dimercapto-succinic acid (DMSA), dimercapto-propane sulfonate (DMPS), alpha
lipoic acid (ALA), calcium disodium versante (CaNa2-EDTA), disodium EDTA,
dimercaprol (BAL), etidronic acid, ethyleneglycoltetraacetic acid,
ehtylenediaminedisuccinic acid, and combinations thereof; iii) emollient selected from the group consisting of lanolin, octyldodecanol, hexyl decanol, oleyl alcohol, decyloleate, isopropyl stearate, isopropyl palmitate, isopropyl myristate, hexyl laureate, dioctyl cyclohexane, PPG-15 stearyl ether, isohexadecane, stearic acid, cetyl alcohol, mineral oil, at least one ester, at least one alcohol, at least one essential oil and extracts thereof, at least one silicone oil, linear polydimethylsiloxanes, cyclic polydimethylsiloxanes, volatile silicones, and combinations thereof; iv) humectant selected from the group consisting of at least one silicone, at least one silicone oil, at least one silicone polymer, at least one cyclized derivative of silicone, at least one polyol, at least one acrylate polymer, at least one biopolymer, and combinations

thereof; v) emulsifying agent selected from the group consisting of oxyalkylenated fatty acid esters of polyols, PEG-100 stearate & glyceryl stearate, oxyalkylenated fatty acid esters of sorbitan, oxyalkylenated (oxyethylenated and/or oxypropylenated) fatty alcohol ethers, alkoxylated or non-alkoxylated sugar esters, sorbitan esters, esters of diacids, esters of fatty alcohols, acrylates, PEG based emulsifiers, polyglyceryl based emulsifiers, silicones, dimethicones, mixture of glycerylmonostearate and of polyethylene glycol stearate and combinations thereof; vi) fragrance selected from the group consisting of blend of essential oils, blend of synthetic aroma compounds, and combination thereof; and vii) cosmetically acceptable additive is selected from the group consisting of colorants, antioxidants, free radical scavengers, vitamins, anti-aging agents, thickeners, and combinations thereof.
[0040] In an embodiment of the present disclosure, there is provided a method of preventing skin infections such as boils, heat rash, prickly heat by inhibiting growth of microorganisms, said method comprising the steps of : (i) obtaining a composition comprising of (a) EDTA, and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein the composition comprises synergistic concentrations of (a) EDTA is in a range of 62.5 – 125 ppm, and (b) Trachyspermum copticum oil in the range of 390.625 - 781.25 ppm, or Melaleuca ericifolia oil in the range of 3125 – 6250 ppm; and (ii) contacting the said composition with skin surface, wherein the said method inhibits growth of microorganisms.
[0041] In an embodiment of the present disclosure, there is provided a method of preventing skin infections such as boils, heat rash, prickly heat by inhibiting growth of microorganisms, said method comprising the steps of : (i) obtaining a composition comprising of (a) EDTA, and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein the composition comprises synergistic ratios of (a) EDTA and Trachyspermum copticum oil in the range of 1:3 to 1:13, or (b) EDTA and Melaleuca ericifolia oil in the range of 1:20 to 1:100; and (ii) contacting said the composition with skin surface, wherein the said method inhibits growth of microorganisms.

[0042] In an embodiment of the present disclosure, there is provided a method of preventing skin infections such as boils, heat rash, prickly heat by inhibiting growth of microorganisms, said method comprising the steps of (i) obtaining a composition comprising of (a) EDTA, and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein the composition comprises a synergistic concentration of (a) 62.5 ppm of EDTA, and (b) 390.6 ppm of Trachyspermum copticum oil, or 3125 ppm of Melaleuca ericifolia oil; and (ii) contacting the said composition with skin surface, wherein the said method inhibits growth of microorganisms.
[0043] In an embodiment of the present disclosure, there is provided a method of preventing skin infections such as boils, heat rash, prickly heat by inhibiting growth of microorganisms, said method comprising the steps of (i) obtaining a formulation comprising of (a) EDTA, (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, and (c) one or more cosmetically acceptable excipients selected from the group consisting of fatty acids, alkalis, viscosity modifiers, polymers, humectants, colors, fragrances, chelating agents, emulsifying agents, emollients and diluents, wherein the formulation comprises a synergistic concentration of (a) 62.5 ppm of EDTA, and (b) 390.6 ppm of Trachyspermum copticum oil, or 3125 ppm of Melaleuca ericifolia oil; and (ii) contacting the said formulation with skin surface, wherein the said method inhibits growth of microorganisms.
[0044] In an embodiment of the present disclosure, there is provided a method of preventing skin infections such as boils, heat rash, prickly heat by inhibiting growth of microorganisms, said method comprising the steps of (i) obtaining a formulation comprising of (a) EDTA, (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, and (c) one or more cosmetically acceptable excipients selected from the group consisting of fatty acids, alkalis, viscosity modifiers, polymers, humectants, colors, fragrances, chelating agents, emulsifying agents, emollients and diluents, wherein the formulation comprises synergistic ratios of (a) EDTA and Trachyspermum copticum oil in the range of 1:3 to 1:13; or (b) EDTA and Melaleuca ericifolia oil in the range of

1:20 to 1:100; and (ii) contacting the said formulation with skin surface, wherein the said method inhibits growth of microorganisms.
[0045] In an embodiment of the present disclosure, there is provided a method for disinfecting hard surfaces containing microorganisms, said method comprising the steps of : (i) obtaining a composition comprising of (a) EDTA, and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein the composition comprises synergistic concentrations of (a) EDTA in a range of 62.5 – 125 ppm, and (b) Trachyspermum copticum oil in the range of 390.625 - 781.25 ppm, or Melaleuca ericifolia oil in the range of 3125 – 6250 ppm; and (ii) contacting the said composition with the hard surface, wherein the said method inhibits growth of microorganisms. [0046] In an embodiment of the present disclosure, there is provided a method for disinfecting hard surfaces containing microorganisms, said method comprising the steps of : (i) obtaining a composition comprising of (a) EDTA, and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein the composition comprises synergistic ratios of (a) EDTA and Trachyspermum copticum oil in the range of 1:3 to 1:13, or (b) EDTA and Melaleuca ericifolia oil in the range of 1:20 to 1:100; and (ii) contacting the said composition with the hard surface, wherein the said method inhibits growth of microorganisms.
[0047] In an embodiment of the present disclosure, there is provided a method for disinfecting hard surfaces containing microorganisms, said method comprising the steps of: (i) obtaining a composition comprising of (a) EDTA, and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein the composition comprises a synergistic concentration of (a) 62.5 ppm of EDTA, and (b) 390.6 ppm of Trachyspermum copticum oil, or 3125 ppm of Melaleuca ericifolia oil; and (ii) contacting the said composition with the hard surface, wherein the said method inhibits growth of microorganisms.
[0048] In an embodiment of the present disclosure, there is provided a method for disinfecting hard surfaces containing microorganisms, said method comprising the steps of: (i) obtaining a formulation comprising of (a) EDTA, (b) Trachyspermum

copticum oil or Melaleuca ericifolia oil, and (c) one or more cosmetically acceptable excipients selected from the group consisting of fatty acids, alkalis, viscosity modifiers, polymers, humectants, colors, fragrances, chelating agents, emulsifying agents, emollients and diluents, wherein the formulation comprises a synergistic concentration of (a) 62.5 ppm of EDTA, and (b) 390.6 ppm of Trachyspermum copticum oil, or 3125 ppm of Melaleuca ericifolia oil; and (ii) contacting the said formulation with the hard surface, wherein the said method inhibits growth of microorganisms.
[0049] In an embodiment of the present disclosure, there is provided a method for disinfecting hard surfaces containing microorganisms, said method comprising the steps of (i) obtaining a formulation comprising of (a) EDTA, (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, and (c) one or more cosmetically acceptable excipients selected from the group consisting of fatty acids, alkalis, viscosity modifiers, polymers, humectants, colors, fragrances, chelating agents, emulsifying agents, emollients and diluents, wherein the formulation comprises synergistic ratios of (a) EDTA and Trachyspermum copticum oil in the range of 1:3 to 1:13; or (b) EDTA and Melaleuca ericifolia oil in the range of 1:20 to 1:100; and (ii) contacting the said formulation with the hard surface, wherein the said method inhibits growth of microorganisms.
[0050] In an embodiment of the present disclosure, there is provided a composition comprising of a) EDTA; and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein synergistic concentrations of (a) EDTA in the said composition is 62.5 ppm, (b) Trachyspermum copticum oil in the said composition is 390.6 ppm or Melaleuca ericifolia oil in the said composition is 3125 ppm, and used for preparing topical formulations for inhibiting growth of microorganisms.
[0051] In an embodiment of the present disclosure, there is provided a composition comprising of a) EDTA; and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, wherein synergistic ratios of (a) EDTA and Trachyspermum copticum oil is in the range of 1:3 to 1:13, or (b) EDTA and Melaleuca ericifolia oil is in the range of 1:20

to 1:100, and used for preparing topical formulations for inhibiting growth of microorganisms.
[0052] In an embodiment of the present disclosure, there is provided a formulation comprising of a) EDTA; and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil, and (c) suitable carriers, diluents, and cosmetically acceptable excipients, wherein synergistic concentrations of (a) EDTA in the said composition is 62.5 ppm, and (b) Trachyspermum copticum oil in the said composition is 390.6 ppm or Melaleuca ericifolia oil in the said composition is 3125 ppm, and used for preparing topical formulations for inhibiting growth of microorganisms.
[0053] In an embodiment of the present disclosure, there is provided a formulation comprising of a) EDTA, and (b) Trachyspermum copticum oil or Melaleuca ericifolia oil; and (c) one or more cosmetically acceptable excipients selected from the group consisting of fatty acids, alkalis, viscosity modifiers, polymers, humectants, colors, fragrances, chelating agents, emulsifying agents, emollients and diluents, wherein the formulation comprises synergistic concentrations of (a) EDTA in the range of 62.5 – 125 ppm, and (b) Trachyspermum copticum oil is in the range of 390.625 - 781.25 ppm, or Melaleuca ericifolia oil in the range of 3125 – 6250 ppm for use in preparing topical formulations for inhibiting growth of microorganisms.
[0054] In an embodiment of the present disclosure, there is provided a formulation comprising of a) EDTA, (b) Trachyspermum copticum oil or Melaleuca ericifolia oil; and (c) one or more cosmetically acceptable excipients selected from the group consisting of fatty acids, alkalis, viscosity modifiers, polymers, humectants, colors, fragrances, chelating agents, emulsifying agents, emollients and diluents, wherein the formulation comprises synergistic ratios of (a) EDTA and Trachyspermum copticum oil in the range of 1:3 to 1:13, or (b) EDTA and Melaleuca ericifolia oil in the range of 1:20 to 1:100, and used for preparing topical formulations for inhibiting growth of microorganisms.
[0055] In an embodiment of the present disclosure, there is provided a personal cleansing formulation comprising (a) at least one fatty acid in a range of 10 to 25% by

weight; (b) at least one alkali in a range of 0.001 to 5% by weight; (c) at least one solubilizer in a range of 5 to 40% by weight; (d) optionally at least one chelating agent in a range of 0.001 to 5 % by weight; (e) EDTA in a range of 62.5 – 125 ppm; and Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or Melaleuca ericifolia oil in a range of 3125 – 6250 ppm; and (f) water in a range of 30 to 70 % by weight.
[0056] The personal cleansing formulation disclosed herein further comprises of at least one fatty acid selected from C8 to C18 fatty acids.
[0057] In another embodiment of the present disclosure, there is provided a personal cleansing composition formulation comprising (a) at least one surfactant in a range of 2 to 20% by weight; (b) at least one polymer in a range of 0.1 to 15% by weight; (c) at least one solubilizer in a range of 0 to 10% by weight; (d) EDTA in a range of 62.5 – 125 ppm; and Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or Melaleuca ericifolia oil in a range of 3125 – 6250 ppm; and (e) water to make up 100 % by weight.
[0058] The cleansing composition formulation disclosed herein comprises at least one surfactant selected from a group that includes amphoteric surfactants, anionic surfactants, non-ionic surfactants and combinations thereof.
[0059] The cleansing formulation disclosed herein comprises of at least one surfactant selected from the group that includes alkyl sulfates, alkyl ether sulfates, alkyl glucosides, anionic acyl sarcosinates, N-acyl glutamates, alkyl sulfosuccinates, alkyl betaines, alpha olefin sulfonates and combinations thereof.
[0060] In still another embodiment of the present disclosure, there is provided a soap bar formulation comprising (a) at least one sodium salts of fatty acids in a range of 30-95% by weight; (b) at least one humectant and emollient in a range of 0.5 to 10 % by weight; (c) at least one binder in a range of 0.5 to 10% by weight; (d) optionally at least one opacifier in a range of 0.001 to 3% by weight; (e) EDTA in a range of 62.5 – 125 ppm; and Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or Melaleuca ericifolia oil in a range of 3125 – 6250 ppm.

[0061] In still another embodiment of the present disclosure, there is provided a topical anti-microbial formulation comprising:
i. at least one chelating agent in a range of 0.001-5% by weight;
ii. at least one polymer in a range of 0.005-5% by weight;
iii. at least one emulsifying agent in a range of 0.01-5% by weight;
iv. at least one humectant in a range of 0.01-10% by weight;
v. at least one preservative in a range of 0.001-1% by weight;
vi. optionally, at least one neutralizing agent in a range of 0-0.75% by
weight;
vii. EDTA in a range of 62.5 – 125 ppm;
viii. Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or
Melaleuca ericifolia oil in a range of 3125 – 6250 ppm; and
ix. Water in a range of 71-99.9% by weight.
[0062] In an embodiment of the present disclosure, there is provided a method of preparing a topical formulation in the form of a hand wash comprising: (i) melting Lauric acid, Myristic acid and Palmitic acid at 75-80°C in water bath; (ii) preparing 10% neutralizing solution of KOH; (iii) neutralizing by adding KOH solution drop wise to EDTA with Trachyspermum copticum oil or Melaleuca ericifolia and mixing at 50-60 rpm; (iv) adding PEG-150 Distearate followed by adding Glycerin at 75°C and mixed at 50-60 rpm; (v) adding fragrance at 40°C and then adding Phenoxyethanol and mixing till all the components are mixed properly at 50-60 rpm, (vi) adding Sodium Chloride to adjust the viscosity, and (vii) adding water to make up the volume to 100%.
[0063] In an embodiment of the present disclosure, there is provided a method of preparing a formulation, wherein the formulation comprises a synergistic concentration of (a) 62.5 – 125 ppm of EDTA, and (b) 390.625 - 781.25 ppm of Trachyspermum copticum oil, or 3125 – 6250 ppm of Melaleuca ericifolia oil. [0064] In an embodiment of the present disclosure, there is provided a method of preparing a formulation, wherein the formulation comprises a synergistic

concentration of (a) 62.5 ppm of EDTA, and (b) 390.6 ppm of Trachyspermum
copticum oil or 3125 ppm of Melaleuca ericifolia oil.
[0065] In an embodiment of the present disclosure, there is provided a method of
preparing a formulation, wherein the formulation comprises synergistic ratios of (a)
EDTA and Trachyspermum copticum oil is in the range of 1:3 to 1:13, or (b) EDTA
and Melaleuca ericifolia oil is in the range of 1:20 to 1:100.
[0066] In an embodiment of the present disclosure, there is provided a composition
which can be formulated in the form of dispersion, emulsion, lotion, cream, ointment,
balm, salve, powder, suspension, gel, aerosol, foam, micelle, soap bar, wipe, liquid
crystal or encapsulation.
[0067] In an embodiment of the present disclosure, there is provided a formulation
selected from the group consisting of soap, shower gel, hand wash, face wash, body
wash, hand / body sanitizer, dusting powder, shampoo, conditioner, deodorant, body
spray, wet wipes, anti-microbial/antiseptic/disinfectant liquid or gel, lip stick, skin
cream, lip balm, foundation, or makeup.
[0068] Although the subject matter has been described in considerable detail with
reference to certain preferred embodiments thereof, other embodiments are possible.
EXAMPLES
[0069] The disclosure will now be illustrated with working examples, which is
intended to illustrate the working of disclosure and not intended to be taken
restrictively to imply any limitations on the scope of the present disclosure.
[0070] Unless defined otherwise, all technical and scientific terms used herein have
the same meaning as commonly understood to one of ordinary skill in the art to which
this disclosure belongs.
[0071] Although methods and materials similar or equivalent to those described
herein can be used in the practice of the disclosed methods and compositions, the
exemplary methods, devices and materials are described herein. It is to be understood

that this disclosure is not limited to particular methods, and experimental conditions described, as such methods and conditions may apply.
Materials and methods
[0072] EDTA: Ethylenediamine Tetraacetic Acid: EDTA enhances the antimicrobial
activity of hydrolysate in Tryptic Soy broth, which is active against Listeria
monocytogenes, enterohaemorrhagic E. coli. EDTA also showed bactericidal effect
against the Staphylococcus epidermidis. EDTA in combination with Lysozyme and
Nisin also inhibit/ reduce growth of E. coli on ham, B. thermosphacta.
[0073] Trachyspermum copticum oil: Trachyspermum copticum oil is obtained by
steam distillation and is a potent antimicrobial agent which shows antimicrobial as
well as antioxidants properties. Studies showed that Trachyspermum copticum oil has
inhibitory effect against E. coli, K. pneumonia and S. aureus. It is also active against
even multi drug resistant microbial pathogens.
[0074] Melaleuca ericifolia oil: Commonly known as swamp paper bark, is a plant
in the myrtle family, Myrtaceae and the genus Melaleuca, native to south-eastern
Australia. Traditionally oil from the leaves was used for medicine. Melaleuca
ericifolia leaves have been analyzed for their oil content and found to contain mostly
1,8-cineole (Eucalyptol) but also significant amounts of α-pinene. The aromatic oil in
the leaves has been used for dental and medical preparations and in scented soaps.
[0075] EDTA was obtained from Hi Media.
[0076] Trachyspermum copticum oil was obtained from IL Health & Beauty Natural
Oils Co. (US)
[0077] Melaleuca ericifolia Oil was obtained from Down Under enterprises
(Australia)
[0078] Mueller Hinton II Broth (cation-adjusted) (MHB) was obtained from BD.
[0079] Nutrient Broth (NB) was obtained from Hi Media.
[0080] Resazurin was obtained from Sigma Aldrich.

[0081] Staphylococcus aureus (MTCC 96) was obtained from Microbial Type Culture Collection and Gene Bank (MTCC).
Anti-microbial activity assay: Preparation of sample solutions and dye
[0082] EDTA: A stock of 100mg/1ml (1, 00,000 ppm) was prepared in MHB Broth.
Further the sample was diluted in MHB Broth to make working stock of 32,000 ppm.
[0083] Trachyspermum copticum oil: A stock of approx. 400mg/1ml (4, 00,000
ppm) was prepared in MHB Broth.
[0084] Melaleuca ericifolia oil: A stock of approx. 800mg/1ml (8, 00,000 ppm) was
prepared in MHB Broth.
[0085] Resazurin: The stock of 1mg/ml was prepared in sterile saline. Further, a
working solution was prepared by dissolving 1ml of stock solution in 4 ml of sterile
saline to get 200µg/ml solution.
Inoculum Preparation
[0086] A loopful of S. aureus culture was cultured in nutrient broth and incubated at 37°C for 24 hours under aerobic condition. Post incubation, the inoculum size was adjusted to 0.1 absorbance at 600 nm (corresponding to approximately 1×108 CFU/mL) using spectrophotometer. Further diluted 100 fold in broth to a concentration of approximately 106 CFU/ml.
Minimum Inhibitory Concentration (MIC) and its determination
[0087] Minimum inhibitory concentration (MIC) is the lowest concentration of an active that prevents visible growth of bacteria. The MIC of an active is determined by preparing solutions of the active at increasing concentrations, incubating the solutions with the separate batches of cultured bacteria, and measuring the results using agar dilution or broth microdilution.

[0088] MIC of sample solution is determined by following these steps: A volume of 100 μl sterile nutrient broth was added to all 96 wells except first three wells of the round bottom microtitre plate A1B1C1 to which 200 μl of above prepared sample solution was added. From the first column A1B1C1, 100 μl of the sample was transferred to the first three wells of second column (A2B2C2) of plate and hence the sample serially diluted till D12E12F12 and 100 μl of the sample discarded from D12E12F12 to maintain same volume of the solution in all wells. To the wells containing sample, 100 μl bacterial suspension (106 CFU/ml) was added such that the final inoculum is 105 CFU/mL and the sample concentration halved. Further G1 to G12 that has bacterial cell suspension + broth medium 100 μl each, served as growth control and H1 to H12 that has only broth medium 200 μl, served as the broth control. The plates were now incubated at 37° C for 24 hours. After 24 hours of incubation, 10 μl of working solution of resazurin (200 μg/ml) was added to all wells. The plates were wrapped with aluminium film and incubated at 37° C for 1 hour. Post incubation, the color change was then assessed visually. Any color change from purple to pink was recorded as positive and indicates growth of microorganisms. The above experiment was performed in triplicate under aseptic conditions.
Checkerboard Assay method:
[0089] The checkerboard assay method provides synergistic concentration testing of anti-microbial compositions, the method determines interaction and potency of two actives when used concurrently. Using Lorian methodology, this assay method determines the effect of the combination of two actives on potency in comparison to their individual activities, and then represented as the Fractional Inhibitory Concentration (FIC) index value. To quantify the interactions between the two actives being tested, the FIC index (the combinations of actives that produced the greatest change from the individual active MIC) value is calculated for each microorganism species and the combination of actives, the steps involved in calculation are as follows:

FIC of Sample A = MIC of sample A in combination with sample B
MIC of sample A alone
FIC of Sample B= MIC of sample B in combination with Sample A
MIC of sample B alone
FIC index = FIC of Sample A + FIC of Sample B
The FIC index is interpreted to infer the effect of various combinations of active:
A concentration of combination of actives is inferred as synergistic if FIC index < 0.5
A concentration of combination of actives is inferred as indifferent if 2 > FIC index > 0.5
A concentration of combination of actives is inferred as antagonistic if FIC index > 2
Example 1
[0090] Effect of EDTA, Trachyspermum copticum oil and Melaleuca ericifolia oil on growth of S. aureus. Table 2. indicates the individual minimum inhibitory concentrations (MIC) for EDTA, Trachyspermum copticum oil and Melaleuca ericifolia oil for inhibiting the growth of S. aureus.

[0092] The checkerboard assay method provides synergistic concentration testing of anti-microbial compositions, the method determines interaction and potency of two actives when used concurrently. Using Lorian methodology, this assay method determines the effect of the combination of two actives on potency in comparison to their individual activities, and then represented as the Fractional Inhibitory Concentration (FIC) index value. To quantify the interactions between the two actives being tested, the FIC index (the combinations of actives that produced the greatest change from the individual active MIC) value is calculated for each microorganism species and the combination of actives, the steps involved in calculation are as follows:
FIC of Sample A = MIC of sample A in combination with sample B
MIC of sample A alone
FIC of Sample B= MIC of sample B in combination with Sample A
MIC of sample B alone
FIC index = FIC of Sample A + FIC of Sample B
The FIC index is interpreted to infer the effect of various combinations of active:
A concentration of combination of actives is inferred as synergistic if FIC index < 0.5
A concentration of combination of actives is inferred as indifferent if 2 > FIC index > 0.5
A concentration of combination of actives is inferred as antagonistic if FIC index > 2
Method of determining synergistic concentration of EDTA and an essential oil using checkerboard Assay:
[0093] The checkerboard assay is carried out through following steps. The concentrations tested for each sample were set four or five dilutions below as well as above the expected MIC. A 96 round bottom well microtitre plate as shown in Figure

1 was taken, 50 μl of the nutrient broth added to all the wells and 100 μl of the broth added to well in 12th column, which acts as a sterility control. 50 μl of EDTA (Sample A) was added in the first column (A1 to H1) and serially diluted on the x-axis till the 10th column (A10 to H10) where 50μl of the solution was discarded to maintain same volume of the solution in all wells. 50 μl of Trachyspermum copticum oil or Melaleuca ericifolia oil (Sample B) was added in the row (A1 to A10), in which each row contains the same amount of Trachyspermum copticum oil or Melaleuca ericifolia oil (Sample B) being diluted on column (A to H). As a result each well in the checkerboard contains a unique combination of the two samples being tested. 100 μl bacterial suspension (106 CFU/ml) of S. aureus culture was added to all the wells. A sterility control was set up from A12 to H12, and growth control (100 μl media + 100 μl bacterial cell suspension) was setup from A11 to H11. The plates were incubated at 25°C for 24hours under aerobic condition. Based on the growth/inhibition of the microbial cultures, the MIC at various concentrations was determined. The MICs determined were used for calculating the synergistic/indifferent/ antagonistic effects. For each checkerboard an MIC plate (for samples alone) was set in parallel. MIC of the combination was compared with the MIC of the actives alone and the fractional inhibitory concentration values (FIC index) were determined as described in the Checkerboard Assay Method.
Example 2
[0094] Effect of combination of EDTA and Trachyspermum copticum oil at various concentrations on the growth of microorganism S. aureus.
[0095] Results of test for synergistic effect of EDTA and Trachyspermum copticum oil samples. Combination of EDTA and Trachyspermum copticum oil at various concentrations was tested for synergistic effect on inhibiting growth of S. aureus.
Table 3. Results of synergistic effect of EDTA and Trachyspermum copticum oil.

The results of the above test indicate that a combination of EDTA in the range of 62.5 ppm to 125ppm, and Trachyspermum copticum oil in the range of 390.625ppm to 781.25ppm, surprisingly shows synergy in inhibiting the growth of microorganism S. aureus.
[0096] Individual MIC data for EDTA and Trachyspermum copticum oil samples is indicated in Table 4.

[0097] The results of test for combined concentrations of EDTA and Trachyspermum copticum oil samples, that indicate indifferent effect on inhibition of S. aureus is indicated in Table 5.
Table 5.
Results of combination of EDTA and Trachyspermum copticum oil with indifferent
effect.
MIC of MIC of
S.No FICE FICT FICindex Inference
E:T T:E
1 250 1562.5 0.5 0.5 1 Indifferent
2 500 3125 1 1 2 Indifferent
MIC of E: T = MIC of EDTA in combination with Trachyspermum copticum oil MIC of T: E = MIC of in Trachyspermum copticum oil in combination with EDTA
The results of above test indicate a combination of EDTA in the range of 250 to 500 ppm, and Trachyspermum copticum oil in the range of 1562.5 to 3125 ppm that shows indifferent effect on the inhibition of growth of S. aureus.
Example 3
[0098] Effect of combination of EDTA and Melaleuca ericifolia oil on growth/inhibition of S. aureus. Combination of EDTA and Melaleuca ericifolia oil at various concentrations was tested for its effect on inhibiting growth of S. aureus. [0099] The synergistic effect of EDTA and Melaleuca ericifolia oil samples is indicated in Table 6.


E:M M:E
1 62.5ppm 3125ppm 0.125 0.125 0.25 Synergistic
2 62.5ppm 6250ppm 0.125 0.25 0.375 Synergistic
3 125ppm 3125ppm 0.25 0.125 0.375 Synergistic
4 125ppm 6250ppm 0.25 0.25 0.5 Synergistic
MIC of E: M= MIC of EDTA in combination with Melaleuca ericifolia oil
MIC of M: E = MIC of in Melaleuca ericifolia oil in combination with EDTA
The results of above test indicate a combination of EDTA in the range of 62.5 ppm to 125ppm, and Melaleuca ericifolia oil in the range of 3125ppm to 6250ppm that surprisingly shows synergy in inhibiting the growth of S. aureus.
[00100] Individual MIC data of EDTA and Melaleuca ericifolia oil samples (or
the positive data) is indicated in Table 7.
Table 7.
Individual MIC data of EDTA and Melaleuca ericifolia oil
Samples MIC against S. aureus (ppm)
EDTA 500
Melaleuca ericifolia oil 25000
The results of above test indicate individual MIC data of 500 ppm for EDTA and 25000 ppm for Melaleuca ericifolia on the inhibition of S. aureus.
[00101] Results of test for combined concentrations of EDTA and Melaleuca ericifolia oil samples, that demonstrate indifferent anti-microbial effect (or the negative data) on S. aureus is indicated in Table 8.
Table 8.

Results of combination of EDTA and Melaleuca ericifolia oil with indifferent effect.
MIC of MIC of
S.No FICE FICM FICindex Inference
E:M M:E
1 250 12500 0.5 0.5 1 Indifferent
2 500 25000 1 1 2 Indifferent
MIC of E: M= MIC of EDTA in combination with Melaleuca ericifolia oil
MIC of M: E = MIC of in Melaleuca ericifolia oil in combination with EDTA
The results of above test indicate a combination of EDTA in the range of 250 ppm to 500 ppm, and Melaleuca ericifolia oil in the range of 12500 ppm to 25000 ppm that shows indifferent effect on the inhibition of growth of S. aureus.
Example 4
[00102] Method of preparation of a formulation comprising of (a) EDTA and
(b) Trachyspermum copticum oil or Melaleuca ericifolia oil is explained in the following steps. Lauric acid, Myristic acid and Palmitic were melted at 75-80°C in water bath. A 10% solution of neutralizing agent KOH was prepared and added drop by drop to a mixture of EDTA and Trachyspermum copticum oil or Melaleuca ericifolia oil. This was mixed at 50-60 rpm. After the neutralization, PEG-150 Distearate was added followed by adding Glycerin at 75°C and then mixed at 50-60 rpm. This was followed by adding fragrance at 40°C and then adding Phenoxyethanol and mixed till all the components are mixed properly at 50-60 rpm. Next Sodium Chloride was added to adjust the viscosity. Finally, water was added to make up the volume to 100%.
[00103] Details of ingredients for example of formulation obtained by the
method disclosed herein, that comprises of EDTA and Trachyspermum copticum oil is indicated in Table 9.

[00104] Details of ingredients for an example of formulation (Hand wash
formulation), obtained by the method disclosed herein, that comprises of EDTA and Melaleuca ericifolia oil are indicated in Table 10.

[00105] Method of preparation of a topical application formulation comprising EDTA and Melaleuca ericifolia oil includes: (a) mixing water, disodium EDTA, carbomer, and acrylates/C10-30 alkyl acrylate crosspolymer under constant stirring at 300-500RPM, preferably 300RPM for 15-20 minutes at a temperature in the range of 22-28°C to obtain a mixture A; (b) mixing glycerin, and methylparaben to said mixture A with constant stirring at 600RPM for 10-15 minutes at a temperature in the range of 22-28°C to obtain a mixture B; (c) mixing

triethanolamine with said mixture B under constant stirring at about 600RPM for 15-20 minutes at a temperature in the range of 22-28°C to obtain a mixture C; (d) mixing EDTA and Melaleuca ericifolia oil with said mixture C with constant stirring and 500-600 rpm for about 10 minutes; and (e) mixing perfume to mixture C and stirring at 500-600 rpm for about 10 minutes at a temperature in the range of 22-28°C to obtain said formulation.
[00106] Details of ingredients for an example of topical application formulation, that comprises EDTA and Melaleuca ericifolia oil are indicated in Table 11.

While this example describes topical application formulation using EDTA with Melaleuca ericifolia oil, it will be understood that a similar formulation can be done using EDTA with Trachyspermum copticum oil.
Example 7
[00107] Details of ingredients for an example of hand wash formulation, that includes EDTA and Trachyspermum copticum oil are indicated in Table 12.
Table 12. Ingredients of an example of hand wash formulation comprising EDTA

[00108] Details of ingredients for an example of face wash formulation, that comprises of EDTA and Trachyspermum copticum oil are indicated in Table 13.
Table 13. Ingredients of an example of face wash formulation comprising EDTA
and Trachyspermum copticum oil.

Example 9
[00109] Details of ingredients for an example of soap bar formulations, that comprises of EDTA and Trachyspermum copticum oil are indicated in Table 14.
Table 14. Ingredients of an example of soap bar formulation comprising EDTA

[00110] While the examples 7-9 describe formulations using EDTA with Trachyspermum copticum oil, it will be understood that a similar formulation can be done using EDTA with Melaleuca ericifolia oil.
[00111] Overall, the present disclosure provides a composition for inhibiting growth of pathogenic microorganisms causing skin infections, the said composition comprises of EDTA and at least one essential oil, wherein essential oil is selected from the group consisting of Trachyspermum copticum oil, and Melaleuca ericifolia oil, which at particular synergistic concentration ranges, surprisingly exhibits synergistic effect on inhibition of growth of pathogenic microorganisms causing skin infections. This effect is only apparent within particular concentration ranges, as data presented above clearly shows that not all ranges give a synergistic effect. The combination of the present disclosure is unexpected as not all combinations tested show a surprising non-additive effect, which is a deviation from the expected results.

[00112] Although the present subject matter has been described with reference to specific embodiments, this description is not meant to be construed in a limiting sense. Various modifications of the disclosed embodiments, as well as alternate embodiments of the subject matter, will become apparent to persons skilled in the art upon reference to the description of the subject matter.

I/We claim:
1. A topical anti-microbial composition comprising synergistic concentrations of:
i. ethylenediaminetetraacetic acid (EDTA), and
ii. at least one essential oil selected from the group consisting of
Trachyspermum copticum oil and Melaleuca ericifolia oil.
2. The composition as claimed in claim 1, wherein the synergistic concentration of EDTA is in a range of 62.5 – 125 ppm.
3. The composition as claimed in any of the claims 1-2, wherein the synergistic concentration of at least one essential oil selected from:
i. Trachyspermum copticum oil is in the range of 390.625 - 781.25 ppm,
and
ii. Melaleuca ericifolia oil is in the range of 3125 – 6250 ppm.
4. The composition as claimed in any of the claims 1-3, wherein the composition
comprises:
EDTA in a range of 62.5 – 125 ppm; and Trachyspermum copticum oil in the range of 390.625 - 781.25 ppm.
5. The composition as claimed in any of the claims 1-3, wherein the composition
comprises:
EDTA in a range of 62.5 – 125 ppm; and Melaleuca ericifolia oil in the range of 3125 – 6250 ppm.
6. The composition as claimed in any of the claims 1-4, wherein the ratio of EDTA and Trachyspermum copticum oil is in the range of 1:3 to 1:13.
7. The composition as claimed in any of the claims 1-3 or 5, wherein the ratio of EDTA and Melaleuca ericifolia oil is in the range of 1:20 to 1:100.
8. An anti-microbial formulation comprising a composition as claimed in any of the claims 1 - 7.
9. The formulation as claimed in claim 8, further comprising one or more
cosmetically acceptable excipients selected from the group consisting of fatty

acids, alkalis, viscosity modifiers, polymers, humectants, colors, fragrances, surfactants, chelating agents, emulsifying agents, emollients and diluents.
10. The formulation as claimed in claim 9, wherein
i. weight concentration of at least one fatty acid is in the range of 10 to
70%;
ii. weight concentration of at least one surfactant is in the range of 0.1 to
20%;
iii. weight concentration of at least one polymer is in the range of 0.005-
2%;
iv. weight concentration of at least one chelating agent is in the range of
0.001-5%;
v. weight concentration of at least one emollient is in the range of 0.001-
10%;
vi. weight concentration of at least one humectant is in the range of 0.01-
5%;
vii. weight concentration of at least one emulsifying agent is in the range
of 0.01-5%;
viii. weight concentration of at least one fragrance is in the range of 0.01-
3%; and
ix. weight concentration of at least one cosmetically acceptable additive
is in the range of 0.001-5%.
11. The formulation as claimed in any of the claims 8-10, wherein
i. at least one polymer is selected from the group consisting of (a) at
least one starch; (b) at least one modified starch; (c) at least one gum;
(d) at least one carbomer; (e) at least one silicone based polymer; (f)
at least one acrylate; (g) at least one cellulose based polymer; and (h)
combinations thereof;
ii. at least one chelating agent is selected from the group consisting of
dimercapto-succinic acid (DMSA), dimercapto-propane sulfonate

(DMPS), alpha lipoic acid (ALA), calcium disodium versante (CaNa2-EDTA), disodium EDTA, dimercaprol (BAL), etidronic acid, ethyleneglycoltetraacetic acid, ehtylenediaminedisuccinic acid, and combinations thereof;
iii. at least one emollient is selected from the group consisting of lanolin,
octyldodecanol, hexyl decanol, oleyl alcohol, decyloleate, isopropyl stearate, isopropyl palmitate, isopropyl myristate, hexyl laureate, dioctyl cyclohexane, PPG-15 stearyl ether, isohexadecane, stearic acid, cetyl alcohol, mineral oil, at least one ester, at least one alcohol, at least one essential oil and extracts thereof, at least one silicone oil, linear polydimethylsiloxanes, cyclic polydimethylsiloxanes, volatile silicones, and combinations thereof;
iv. at least one humectant selected from the group consisting of at least
one silicone, at least one silicone oil, at least one silicone polymer, at
least one cyclized derivative of silicone, at least one polyol, at least
one acrylate polymer, at least one biopolymer, and combinations
thereof;
v. at least one emulsifying agent selected from the group consisting of
oxyalkylenated fatty acid esters of polyols, PEG-100 stearate and glyceryl stearate, oxyalkylenated fatty acid esters of sorbitan, oxyalkylenated (oxyethylenated and/or oxypropylenated) fatty alcohol ethers, alkoxylated or non-alkoxylated sugar esters, sorbitan esters, esters of diacids, esters of fatty alcohols, acrylates, PEG based emulsifiers, polyglyceryl based emulsifiers, silicones, dimethicones, mixture of glycerylmonostearate and of polyethylene glycol stearate and combinations thereof;
vi. at least one fragrance selected from the group consisting of blend of
essential oils, blend of synthetic aroma compounds, and combinations thereof; and

vii. at least one cosmetically acceptable additive is selected from the
group consisting of colorants, antioxidants, free radical scavengers, vitamins, anti-aging agents, thickeners, and combinations thereof.
12. An anti-microbial personal cleansing formulation, comprising:
i. at least one C8 to C18 fatty acid in a range of 10 to 25% by weight;
ii. at least one alkali in a range of 0.001 to 5% by weight;
iii. at least one solubilizer in a range of 5 to 40% by weight;
iv. optionally, at least one chelating agent in a range of 0.001 to 5 % by
weight;
v. EDTA in a range of 62.5 – 125 ppm;
vi. Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or
Melaleuca ericifolia oil in a range of 3125 – 6250 ppm; and
vii. water to make up 100% weight.
13. An anti-microbial personal cleansing formulation, comprising:
i. at least one surfactant in a range of 2 to 20% by weight;
ii. at least one polymer in a range of 0.1 to 15% by weight;
iii. at least one solubilizer in a range of 0 to 10% by weight;
iv. optionally, at least one chelating agent in a range of 0.001 – 5 % by
weight;
v. EDTA in a range of 62.5 – 125 ppm;
vi. Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or
Melaleuca ericifolia oil in a range of 3125 – 6250 ppm; and
vii. water to make up 100% weight.
14. An anti-microbial soap bar formulation, comprising:
i. at least one sodium salt of fatty acid in a range of 30-95% by weight;
ii. at least one humectant and emollient in a range of 0.5 to 10% by
weight;
iii. at least one binder in a range of 0.5 to 10% by weight;
iv. optionally at least one opacifier in a range of 0.001 to 3% by weight;

v. optionally, at least one chelating agent in a range of 0.001 – 5% by
weight;
vi. EDTA in a range of 62.5 – 125 ppm;
vii. Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or
Melaleuca ericifolia oil in a range of 3125 – 6250 ppm; and
viii. water to make up 100% weight.
15. A topical anti-microbial formulation, comprising:
i. at least one polymer in a range of 0.005-5% by weight;
ii. at least one emulsifying agent in a range of 0.01-5% by weight;
iii. at least one humectant in a range of 0.01-10% by weight;
iv. at least one preservative in a range of 0.001-1% by weight;
v. optionally, at least one neutralizing agent in a range of 0-0.75% by
weight;
vi. optionally, at least one chelating agent in a range of 0.001- 5 % by
weight;
vii. EDTA in a range of 62.5 – 125 ppm;
viii. Trachyspermum copticum oil in a range of 390.625 - 781.25 ppm or
Melaleuca ericifolia oil in a range of 3125 – 6250 ppm; and
ix. water to make up 100% weight.